Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer

Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer

Achievement of complete Pathomorphologic Response (pCR) after neoadjuvant therapy of breast cancer significantly improves long-term treatment outcome. Correlation between pCR and long-term treatment outcome is strongest in HER2-positive breast cancer; this data clearly supports use of double HER2-bl...

Full description

Bibliographic Details
Main Authors: V. A. Kostorov, T. Yu. Semiglazova, A. V. Pavlysh
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-07-01
Series:Медицинский совет
Subjects:
her-positive breast cancer
neoadjuvant therapy
double anti-her2-blockade
pertuzumab
trastuzumab
Online Access:https://www.med-sovet.pro/jour/article/view/2545

Similar Items

Similar Items